lumateperone   Click here for help

GtoPdb Ligand ID: 9099

Synonyms: Caplyta® | ITI-007
Approved drug
lumateperone is an approved drug (FDA (2019))
Compound class: Synthetic organic
Comment: Lumateperone (ITI-007) is an antipsychotic, with a novel mechanism of action, making it the first-in class agent of its type [3,6]. Note that the approved drug contains lumateperone tosylate (PubChem CID 44241743).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 26.79
Molecular weight 393.22
XLogP 4.26
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(cc1)C(=O)CCCN1CCC2C(C1)c1cccc3c1N2CCN3C
Isomeric SMILES Fc1ccc(cc1)C(=O)CCCN1CCC2C(C1)c1cccc3c1N2CCN3C
InChI InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3
InChI Key HOIIHACBCFLJET-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Lumateperone was initially progressed to clinical trials for the treatment of schizophrenia, bipolar depression, and Alzheimer's disease (principally to manage agitation) [2]. In Phase 1 and Phase 2 clinical trials, lumateperone treatment demonstrated improved sleep maintenance, antipsychotic efficacy, and clinical signals consistent with reduction in negative symptoms associated with schizophrenia, depression and anxiety, and other symptoms associated with impaired social function. FDA approval as a treatment for schizophrenia was granted in December 2019. Since then, potential clinical indications and trials have been expanded to include bipolar disorder (mania), treatment resistant depression, stuttering, social anxiety disorder and irritability associated with autism spectrum disorder.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Lumateperone simultaneously modulates serotonin, dopamine, and glutamate signalling, which are three neurotransmitter pathways that are implicated in severe mental illness. Low dose lumateperone behaves as a highly potent 5-HT2A receptor antagonist. As the dose is increased, engagement with additional molecular targets occurs with the compound showing modest dopamine receptor modulation and modest inhibition of serotonin transporters [5]. In relation to its effects on dopamine signalling via D2 receptors, lumateperone acts as a pre-synaptic partial agonist and post-synaptic antagonist.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06706674 Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients Phase 3 Interventional Intra-Cellular Therapies, Inc.
NCT07623135 Lumateperone for Late-Life Depression Phase 3 Interventional Washington University School of Medicine
NCT07734103 Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder Phase 2 Interventional CSTrials Inc.
NCT07747389 A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder Phase 3 Interventional Intra-Cellular Therapies, Inc.
NCT07799493 Caplyta Versus Placebo for Adults With Social Anxiety Disorder Phase 4 Interventional IMA Clinical Research
NCT04959032 Lumateperone for the Prevention of Relapse in Patients With Schizophrenia Phase 3 Interventional Intra-Cellular Therapies, Inc.
NCT02469155 A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment Phase 3 Interventional Intra-Cellular Therapies, Inc. 1